Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines

Radiation Oncology

Volumn 10, Issue 1, 2015, Pages

  Wohlleben, Gisela ^a   Scherzad, Agmal ^a   Güttler, Antje ^b   Vordermark, Dirk ^b   Kuger, Sebastian ^a,c   Flentje, Michael ^a   Polat, Buelent ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Glioblastoma multiforme; Head and neck cancer; Hypoxia; Irradiation; Osteopontin

Indexed keywords

MESSENGER RNA; OSTEOPONTIN; TUMOR MARKER;

ARTICLE; CANCER CELL LINE; CANCER GROWTH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GAMMA IRRADIATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYPOXIA; METASTASIS; OPN GENE; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE STUDY; RADIATION DOSE; RADIATION EXPOSURE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; BIOSYNTHESIS; CELL HYPOXIA; HEAD AND NECK TUMOR; METABOLISM; RADIATION RESPONSE; TUMOR CELL LINE; WESTERN BLOTTING;

BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; HEAD AND NECK NEOPLASMS; HUMANS; OSTEOPONTIN; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84938819197     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/s13014-015-0473-x     Document Type: Article

References (28)

1. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225-39.
2. Bittner MI, Grosu AL. Hypoxia in Head and Neck Tumors: Characteristics and Development during Therapy. Frontiers in oncology. 2013;3:223.
3. Thorwarth D, Monnich D, Zips D. Methodological aspects on hypoxia PET acquisition and image processing. Q J Nucl Med Mol Imaging. 2013;57(3):235-43.
4. Halmos GB, Bruine De Bruin L, Langendijk JA, Van Der Laan BF, Pruim J, Steenbakkers RJ. Head and neck tumor hypoxia imaging by 18 F-fluoroazomycin-arabinoside (18 F-FAZA)-PET: a review. Clin Nucl Med. 2014;39(1):44-8.
5. Ostheimer C, Bache M, Guttler A, Kotzsch M, Vordermark D. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther Onkol. 2014;190(3):276-82.
6. Said HM, Hagemann C, Staab A, Stojic J, Kuhnel S, Vince GH, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007;83(3):398-405.
7. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008;9(4):342-51.
8. Bache M, Reddemann R, Said HM, Holzhausen HJ, Taubert H, Becker A, et al. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys. 2006;66(5):1481-7.
9. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer. 2008;8(3):212-26.
10. Chong HC, Tan CK, Huang RL, Tan NS. Matricellular proteins: a sticky affair with cancers. J Oncol. 2012;2012:351089.
11. Petrik D, Lavori PW, Cao H, Zhu Y, Wong P, Christofferson E, et al. Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol. 2006;24(33):5291-7.
12. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara Jr PN, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008;26(29):4771-6.
13. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005;6(10):757-64.
14. Guttler A, Giebler M, Cuno P, Wichmann H, Kessler J, Ostheimer C, et al. Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy. Radiother Oncol. 2013;108(3):535-40.
15. Likui W, Hong W, Shuwen Z. Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg. 2010;14(1):74-81.
16. Snitcovsky I, Leitao GM, Pasini FS, Brunialti KC, Mangone FR, Maistro S, et al. Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy. Archives of otolaryngology--head & neck surgery. 2009;135(8):807-11.
17. Lim AM, Rischin D, Fisher R, Cao H, Kwok K, Truong D, et al. Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial. Clin Cancer Res. 2012;18(1):301-7.
18. Caradec J, Sirab N, Keumeugni C, Moutereau S, Chimingqi M, Matar C, et al. 'Desperate house genes': the dramatic example of hypoxia. Br J Cancer. 2010;102(6):1037-43.
19. Zhong H, Simons JW. Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun. 1999;259(3):523-6.
20. Polat B, Wohlleben G, Katzer A, Djuzenova CS, Technau A, Flentje M. Influence of osteopontin silencing on survival and migration of lung cancer cells. Strahlenther Onkol. 2013;189(1):62-7.
21. Hahne JC, Meyer SR, Kranke P, Dietl J, Guckenberger M, Polat B, et al. Studies on the role of osteopontin-1 in endometrial cancer cell lines. Strahlenther Onkol. 2013;189(12):1040-8.
22. Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, et al. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol. 2010;5:82.
23. Chang SH, Minai-Tehrani A, Shin JY, Park S, Kim JE, Yu KN, et al. Beclin1-induced Autophagy Abrogates Radioresistance of Lung Cancer Cells by Suppressing Osteopontin. J Radiat Res. 2012;53(3):422-32.
24. Le QT, Kong C, Lavori PW, O'Byrne K, Erler JT, Huang X, et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2007;69(1):167-75.
25. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006;12(5):1507-14.
26. Bache M, Rot S, Kessler J, Guttler A, Wichmann H, Greither T, et al. mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma. Oncol Rep. 2015;33(6):3155-61.
27. Hui EP, Sung FL, Yu BK, Wong CS, Ma BB, Lin X, et al. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin Cancer Res. 2008;14(21):7080-7.
28. Zhu Y, Denhardt DT, Cao H, Sutphin PD, Koong AC, Giaccia AJ, et al. Hypoxia upregulates osteopontin expression in NIH-3 T3 cells via a Ras-activated enhancer. Oncogene. 2005;24(43):6555-63.